Compare DraftKings Inc (DKNG) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Cassava Sciences Inc — how do they compare? DraftKings Inc trades at $25.33 (market cap $12.05B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: DraftKings Inc is far larger — about 252.4× Cassava Sciences Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | FLNA | |
|---|---|---|
Market Cap | $12.05B | $47.75M |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $4.64 |
52-Week Low | $20.72 | $0.87 |
Enterprise Value | $12.98B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $24.03, up 8.39% today, but remains under pressure with a bearish technical signal. Recent Q2 2026 earnings missed expectations, with an EPS loss of $0.14 versus a $0.02 profit forecast. Revenue grew to $6.05 billion in 2025, but net income margins are negative. Analyst consensus is bullish with a $33.86 price target, though news highlights competition from prediction markets and promotional costs.
The outlook is mixed: strong revenue growth and positive operating cash flow support long-term potential, but profitability challenges and competitive threats pose risks. Upside depends on execution in new markets and cost management, while investor sentiment is cautious amid recent earnings misses and bearish technical trends.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
